Τίτλος:
Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Anti-MAG demyelinating neuropathy is difficult to treat. All immunotherapies have failed except for rituximab, a chimeric B-cell-depleting monoclonal antibody against CD20, that helps up to 40% of patients based on 2 controlled and several uncontrolled series.1-3 Because the majority of these patients are left disabled, stronger anti-B-cell agents might be promising. © American Academy of Neurology.
Συγγραφείς:
Rakocevic, G.
Martinez-Outschoorn, U.
Dalakas, M.C.
Περιοδικό:
Neurology® Neuroimmunology and Neuroinflammation
Εκδότης:
Lippincott Williams and Wilkins
DOI:
10.1212/NXI.0000000000000460
